TD Cowen analyst Tyler Van Buren raised the firm’s price target on Travere Therapeutics (TVTX) to $24 from $20 and keeps a Buy rating on the shares. The firm updated its model as a preview to Q4 results to reflect the company s pre-reported Q4 Filspari revenue of $50M. They also increased 2025 Filspari estimate to $210M to account for continued steady new patient growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX: